Lunit to Present Five Research Abstracts at ASCO in the United States

On April 22, Lunit, a medical artificial intelligence (AI) company, announced that it will present five research abstracts utilizing its AI biomarker platform, Lunit SCOPE, at the 2026 American Society of Clinical Oncology (ASCO 2026), which will be held in Chicago, United States, from May 29 to June 2, 2026.

In particular, a phase 1b/2 clinical trial evaluating the efficacy of trastuzumab, nivolumab, and cytotoxic chemotherapies (gemcitabine and cisplatin) as first-line treatment for patients with HER2-positive biliary tract cancer, led by Professor Lee Chungkeun of Yonsei University College of Medicine, has been selected for a Rapid Oral Presentation. Lunit participated in this study and provided analytical results using Lunit SCOPE.

Additionally, Lunit will present four poster abstracts, including: ▲ AI-based spatial analysis of endothelial cells and tumor-infiltrating lymphocytes (TILs) to predict axitinib (Inlyta) response in adenoid cystic carcinoma; ▲ AI-based spatial analysis of the tumor microenvironment in microsatellite stable (MSS) metastatic colorectal cancer patients receiving immunotherapy; ▲ AI-based tumor microenvironment profiling in HER2-overexpressing non-small cell lung cancer; and ▲ a multi-omics post hoc analysis of a clinical trial investigating the potential to overcome immune resistance through TGF-beta (transforming growth factor-beta) inhibition in advanced gastric cancer.

Bumseok Seo, CEO of Lunit, commented, "The selection of Lunit SCOPE-based studies across a diverse range of cancers—from biliary tract cancer to lung, colorectal, and gastric cancers—demonstrates the rapidly expanding applicability of AI biomarkers. As real-world clinical trials increasingly adopt Lunit SCOPE, we will continue to advance research and commercialization to establish it as a core tool in treatment decision-making."

Founded in 1964, the American Society of Clinical Oncology (ASCO) is recognized alongside the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO) as one of the world's three major cancer societies. Each year, more than 40,000 medical professionals from over 120 countries attend the event. Lunit has participated in ASCO for eight consecutive years since 2019, presenting the latest research results related to AI biomarkers.

This content was produced with the assistance of AI translation services.